OABI•businesswire•
OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors
Summary
EMERYVILLE, Calif. & DENVER--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) and ArrowMark Partners (“ArrowMark”) today announced the signing of a license and services agreement for novel OmniAb-derived antibody discovery programs with Mabtrx Biosciences, a wholly owned subsidiary of AMVKG LS, a joint venture (JV) between ArrowMark and Viking Global Investors (“Viking”). Under the terms of the license and services agreement, OmniAb will receive revenue for services performed as well as potential e
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 17, 2025 by businesswire